Loading
VBI Vaccines Inc/BC Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by GILLIS STEVEN, was filed 18 Jul 2023.
VBI Vaccines Inc/BC: what insiders have been doing
VBI Vaccines Inc/BC, classified in the Healthcare & Pharma sector, is a listed company based in Cambridge, United States, founded in 2001. Its insiders report their share dealings to SEC (Form 4). The past year has been quiet: not a single insider filing for VBI Vaccines Inc/BC. The previous disclosure was published on 18 July 2023.
Over the whole record (from 2017), the tally stands at 41 purchases and 8 sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
85
Thresholds
n/a
Buy Volume
€59M
41 ops. · all time
Sell Volume
€16M
8 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$7.5M
Net income-US$79.9M-1069.3% margin
Last declaration on 18 July 2023
Declarations85 total
609,090 shares@ US$1.65100.0% of flowCommon Shares, no par value per shareSEC:0001493152-23-024786:0
Canonical exit: 8 Oct 2023 (T+90)
1,832,563 shares@ US$0.130.3% of flowCommon StockSEC:0000899243-23-010886:1
4,251,563 shares@ US$0.110.7% of flowCommon StockSEC:0000899243-23-010886:2
4,810,623 shares@ US$0.165.1% of flowCommon StockSEC:0000899243-23-010886:0
8,200 shares@ US$2.4492100.0% of flowCommon Shares, no par value per shareSEC:0001493152-21-030541:0
Canonical exit: 3 Mar 2022 (T+90)
2,707,463 shares@ US$3.3157.2% of flowCommon StockSEC:0001062993-21-012195:0
145,548 shares@ US$3.800.7% of flowCommon StockSEC:0001062993-21-006119:1
500,709 shares@ US$3.8011.6% of flowCommon StockSEC:0001062993-21-006119:0
465,936 shares@ US$2.751.6% of flowCommon StockSEC:0001062993-21-005610:1
1,102,179 shares@ US$4.005.5% of flowCommon StockSEC:0001062993-21-005610:2
320,388 shares@ US$4.001.6% of flowCommon StockSEC:0001062993-21-005610:3
1,602,888 shares@ US$2.7526.2% of flowCommon StockSEC:0001062993-21-005610:0
9,090,909 shares@ US$1.1040.2% of flowCommon StockSEC:0000899243-20-011371:0
Canonical exit: 23 Jul 2020 (T+90)
14,500 shares@ US$0.507.5% of flowCommon Shares, no par value per shareSEC:0001493152-19-015126:0
Canonical exit: 29 Dec 2019 (T+90)
40,000 shares@ US$0.5020.5% of flowCommon Shares, no par value per shareSEC:0001493152-19-015126:1
Canonical exit: 2 Jan 2020 (T+90)
10,000 shares@ US$0.482214.3% of flowCommon Shares, no par value per shareSEC:0001493152-19-014801:0
Canonical exit: 30 Dec 2019 (T+90)
12,000 shares@ US$0.473100.0% of flowCommon Shares, no par value per shareSEC:0001493152-19-014802:0
Canonical exit: 30 Dec 2019 (T+90)
150,000 shares@ US$0.50329.8% of flowCommon Shares, no par value per shareSEC:0001493152-19-014759:0
Canonical exit: 29 Dec 2019 (T+90)
20,000,000 shares@ US$0.5017.9% of flowCommon StockSEC:0000899243-19-024191:0
Canonical exit: 22 Dec 2019 (T+90)
8,000 shares@ US$1.076.6% of flowCommon Shares, no par value per shareSEC:0001493152-19-009942:0
Canonical exit: 25 Sept 2019 (T+90)
10,000 shares@ US$0.786.0% of flowCommon Shares, no par value per shareSEC:0001493152-19-009492:0
Canonical exit: 18 Sept 2019 (T+90)
42,000 shares@ US$0.8928.9% of flowCommon Shares, no par value per shareSEC:0001493152-19-009492:1
Canonical exit: 18 Sept 2019 (T+90)
1,000,000 shares@ US$0.651.1% of flowCommon StockSEC:0001012975-19-000447:0
Canonical exit: 16 Sept 2019 (T+90)
144,000 shares@ US$0.731533.7% of flowCommon Shares, no par value per shareSEC:0001493152-19-009422:0
Canonical exit: 17 Sept 2019 (T+90)
8,000 shares@ US$0.735717.0% of flowCommon Shares, no par value per shareSEC:0001493152-19-009424:0
Canonical exit: 17 Sept 2019 (T+90)
25 of 85 declarations
About VBI Vaccines Inc/BC
VBI Vaccines Inc/BC (ticker: VBIV) is a United States-linked biopharmaceutical company listed on the NASDAQ. For international equity investors, it represents a small-cap, high-risk vaccine and immunology platform story rather than a broad-based commercial pharma franchise. The company traces its roots to Variation Biotechnologies (VBI) and its current structure was formed through a series of mergers completed between 2014 and 2016. Its corporate headquarters are in Cambridge, Massachusetts, United States, placing it in one of the world’s most important biotech clusters, while research and development activities are maintained in Ottawa, Canada, and GMP manufacturing capabilities are located in Rehovot, Israel. ([vbivaccines.com](https://www.vbivaccines.com/contact/?utm_source=openai))
VBI’s business model is built around proprietary vaccine science, primarily its enveloped virus-like particle, or eVLP, platform. The company has developed candidates designed to mimic the natural presentation of viruses and trigger strong immune responses. Its best-known asset has been its three-antigen hepatitis B vaccine, marketed under names including Sci-B-Vac, PreHevbrio, and PreHevbri depending on the market and partner structure. Beyond hepatitis B, VBI has pursued a broader pipeline that has included therapeutic hepatitis B programs, cytomegalovirus candidates, oncology immunotherapy programs, and coronavirus vaccine candidates. ([vbivaccines.com](https://www.vbivaccines.com/press-releases/oct-2017-offering-closing/?utm_source=openai))
Read moreShow less
From a competitive standpoint, VBI occupies a niche position in the global vaccine landscape. It does not compete with large-cap vaccine manufacturers on scale, but rather on differentiation of its delivery platform and antigen presentation approach. That makes the investment case highly binary: clinical data, regulatory decisions, and commercialization partnerships matter more than traditional volume-driven market share metrics. The company has also relied on partnerships to extend reach, including collaborations that supported commercialization in the United States, Europe, Canada, and parts of Asia-Pacific. This suggests a strategy focused on value realization through licensing and partnering rather than a fully integrated global sales model. ([vbivaccines.com](https://www.vbivaccines.com/press-releases/syneos-health-commercialization-partner/?utm_source=openai))
Geographically, VBI has a notably international operating footprint for a company of its size. The Cambridge headquarters supports corporate leadership, business development, commercialization, communications, and investor relations. Ottawa hosts discovery and preclinical work, while the Rehovot facility handles manufacturing and release activities. That footprint supports development and supply-chain flexibility, but also adds execution complexity and dependence on cross-border operations. Recent company disclosures have highlighted revenue contributions from product sales and partnership arrangements in 2023, while more recent communications also referenced a voluntary nationwide recall of PreHevbrio in the context of discontinuing company operations. For investors, VBIV remains an NASDAQ-listed, science-driven special situation where the valuation thesis hinges on intellectual property, partnering optionality, and the status of legacy vaccine assets. ([vbivaccines.com](https://www.vbivaccines.com/?utm_source=openai))
